throbber
From the Divisions of Nephrology and
`Hypertension (J.J.B.), Pulmonary Medi-
`cine (L.R.Y.), Neurology (G.C., J.M.L.,
`D.N.F.), Radiology (V.J.S., T.L., A.S.B.),
`and Biostatistics (J.B., S.S.), Cincinnati
`Children’s Hospital Medical Center; and
`the Division of Pulmonary and Critical
`Care, University of Cincinnati College of
`Medicine (F.X.M., L.R.Y., J.M.E.) — both
`in Cincinnati. Address reprint requests to
`Dr. Bissler at Cincinnati Children’s Hos-
`pital Medical Center, MLC 7022, 3333 Bur-
`net Ave., Cincinnati, OH 45229-3039, or
`at john.bissler@cchmc.org.
`
`Drs. McCormack, Young, and Franz con-
`tributed equally to the article.
`
`N Engl J Med 2008;358:140-51.
`Copyright © 2008 Massachusetts Medical Society.
`
`T h e ne w e ngl a nd jou r na l o f m e dicine
`
`original article
`
`Sirolimus for Angiomyolipoma in Tuberous
`Sclerosis Complex or Lymphangioleiomyomatosis
`John J. Bissler, M.D., Francis X. McCormack, M.D., Lisa R. Young, M.D.,
`Jean M. Elwing, M.D., Gail Chuck, L.M.T., Jennifer M. Leonard, R.N.,
`Vincent J. Schmithorst, Ph.D., Tal Laor, M.D., Alan S. Brody, M.D.,
`Judy Bean, Ph.D., Shelia Salisbury, M.S., and David N. Franz, M.D.
`
`ABSTR ACT
`
`Background
`Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic
`lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis
`genes resulting in constitutive activation of the mammalian target of rapamycin
`(mTOR). The drug sirolimus suppresses mTOR signaling.
`
`Methods
`We conducted a 24-month, nonrandomized, open-label trial to determine whether
`sirolimus reduces the angiomyolipoma volume in patients with the tuberous scle-
`rosis complex or sporadic lymphangioleiomyomatosis. Sirolimus was administered
`for the first 12 months only. Serial magnetic resonance imaging of angiomyolipo-
`mas and brain lesions, computed tomography of lung cysts, and pulmonary-func-
`tion tests were performed.
`
`Results
`Of the 25 patients enrolled, 20 completed the 12-month evaluation, and 18 com-
`pleted the 24-month evaluation. The mean (±SD) angiomyolipoma volume at 12
`months was 53.2±26.6% of the baseline value (P<0.001) and at 24 months was
`85.9±28.5% of the baseline value (P = 0.005). At 24 months, five patients had a per-
`sistent reduction in the angiomyolipoma volume of 30% or more. During the period
`of sirolimus therapy, among patients with lymphangioleiomyomatosis, the mean
`forced expiratory volume in 1 second (FEV1) increased by 118±330 ml (P = 0.06), the
`forced vital capacity (FVC) increased by 390±570 ml (P<0.001), and the residual
`volume decreased by 439±493 ml (P = 0.02), as compared with baseline values. One
`year after sirolimus was discontinued, the FEV1 was 62±411 ml above the baseline
`value, the FVC was 346±712 ml above the baseline value, and the residual volume
`was 333±570 ml below the baseline value; cerebral lesions were unchanged. Five
`patients had six serious adverse events while receiving sirolimus, including diar-
`rhea, pyelonephritis, stomatitis, and respiratory infections.
`
`Conclusions
`Angiomyolipomas regressed somewhat during sirolimus therapy but tended to in-
`crease in volume after the therapy was stopped. Some patients with lymphangio-
`leiomyomatosis had improvement in spirometric measurements and gas trapping
`that persisted after treatment. Suppression of mTOR signaling might constitute an
`ameliorative treatment in patients with the tuberous sclerosis complex or sporadic
`lymphangioleiomyomatosis. (ClinicalTrials.gov number, NCT00457808.)
`
`140
`
`n engl j med 358;2 www.nejm.org
`
`january 10, 2008
`
`The New England Journal of Medicine
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0001
`
`

`
`Sirolimus for Angiomyolipoma in Tuberous Sclerosis or Lymphangioleiomyomatosis
`
`The tuberous sclerosis complex, a
`
`tumor-suppressor syndrome caused by mu-
`tations in the tuberin gene (TSC2) or the
`hamartin gene (TSC1), is characterized by hamar-
`tomas in organs including the brain, kidney, lung,
`skin, and heart.1 Angiomyolipomas — tumors
`rich in fat, muscle, and blood vessels that can
`hemorrhage or infiltrate the kidney, leading to
`renal failure — develop in approximately 80% of
`patients.2 Lymphangioleiomyomatosis, the major
`pulmonary manifestation in women with the tu-
`berous sclerosis complex, is a progressive lung
`disease characterized by infiltration of smooth-
`muscle cells and formation of parenchymal cysts.3
`Sporadic lymphangioleiomyomatosis can develop
`in women without the tuberous sclerosis complex,
`owing to somatic mutations in tuberous sclero-
`sis genes.4 The cells comprising the lymphangio-
`leiomyomatosis lesions and angiomyolipomas
`appear to arise from a common source.5
`The hamartin–tuberin complex regulates the
`activity of the target of rapamycin complex 1,
`which lies downstream of cellular pathways con-
`trolling cell growth and proliferation. Abnormal
`signaling through the target of rapamycin com-
`plex 1 is involved in a number of tumor-suppres-
`sor syndromes6-8 and cancers.9 Sirolimus, an im-
`munosuppressive agent approved by the Food and
`Drug Administration, forms a complex with FK
`binding protein 12 and inactivates the target of
`rapamycin complex 1, abrogating the signaling.
`Sirolimus corrects size defects in tuberin-defi-
`cient Drosophila melanogaster cells and induces the
`apoptosis of renal cystadenomas and hepatic
`hemangiomas in rodent models of the tuberous
`sclerosis complex.10,11 In our phase 1–2, proof-of-
`concept study, we aimed to determine whether
`sirolimus has an effect on the volume of angio-
`myolipomas in patients with the tuberous sclero-
`sis complex, sporadic lymphangioleiomyomatosis,
`or both.
`
`Methods
`
`Selection and Enrollment of Patients
`The consecutive enrollment of male and female
`patients, 18 to 65 years of age, began in May 2003
`and continued until November 2004, when the
`target of 25 patients was reached. The voluntary
`provision of written informed consent, a con-
`firmed diagnosis of the tuberous sclerosis com-
`
`plex12 or sporadic lymphangioleiomyomatosis,13,14
`the use of contraception (for female patients), and
`the presence of at least one angiomyolipoma 1 cm
`or more in the largest dimension were required
`for participation. Exclusion criteria were the use
`of continuous supplemental oxygen; concurrent
`infection; surgery within 8 weeks before the start
`of sirolimus therapy; current or planned preg-
`nancy; lactation; substantial hematologic, renal,
`hepatic, or metabolic abnormalities; and the use
`of an investigational drug within 30 days before
`entrance into the study. All female patients who
`could conceive were administered a pregnancy
`test before enrollment and at each visit.
`
`Study Design
`The study was conducted at the General Clinical
`Research Center of the Cincinnati Children’s Hos-
`pital Medical Center. Patients were recruited from
`the Tuberous Sclerosis Clinic and the patient reg-
`istry of the LAM Foundation. The institutional
`review board approved the study protocol, and a
`data and safety monitoring board reviewed trial
`progress semiannually.
`In our open-label, phase 1–2 trial, all patients
`received sirolimus for 1 year and were then fol-
`lowed for an additional year after the therapy was
`stopped. The primary end point was angiomyoli-
`poma volume at 1 year, and secondary end points
`included angiomyolipoma volume at 2 years and
`spirometric measurements, lung volumes, diffus-
`ing capacity, results of the 6-minute walk test, and
`the percentage of the cyst volume at 1 and 2 years.
`Patients were seen at baseline; at week 2, 3, or 4;
`and at months 2, 4, 6, 9, 12, 18, and 24. The
`angiomyolipomas were imaged at all visits except
`the visit at week 2, 3, or 4 and the visit at month
`9. Sirolimus dosing was based on serum target
`levels that would prevent rejection in patients who
`had renal transplants. The initial sirolimus dose
`was 0.25 mg per square meter of body-surface
`area. Sirolimus levels were measured at 2 weeks,
`and the dosage was adjusted to achieve a blood
`sirolimus level between 1 and 5 ng per milliliter.
`If the target angiomyolipoma lesions had not de-
`creased by 10% of the baseline value in the lon-
`gest coronal-plane dimension at the 2-month
`visit, the dose was increased to achieve a blood
`sirolimus level of 5 to 10 ng per milliliter. At the
`4-month visit, if the threshold of a 10% reduc-
`tion from the baseline value had not been reached,
`
`n engl j med 358;2 www.nejm.org
`
`january 10, 2008
`
`141
`
`The New England Journal of Medicine
`
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
`
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0002
`
`

`
`T h e ne w e ngl a nd jou r na l o f m e dicine
`
`the dose was increased to achieve a blood siroli-
`mus level of 10 to 15 ng per milliliter. The dose
`chosen at the 4-month visit was continued through
`12 months.
`
`performed at baseline; if the results were posi-
`tive, during subsequent visits, spirometric variables
`were measured after the administration of a bron-
`chodilator.
`
`Imaging
`Cross-sectional brain and abdominal evaluations
`were performed by means of magnetic resonance
`imaging (MRI) with the use of a clinical 1.5-Tesla
`system (General Electric Medical Systems). Coro-
`nal and axial fast spin–echo T2-weighted sequenc-
`es were performed with and without fat suppres-
`sion. At baseline, up to five lesions per patient
`were identified for volume measurement through-
`out the study. The volumes for all lesions from a
`given time point were averaged for use in analy-
`ses. Computed tomography (CT) of the lungs was
`performed during full inspiration and during full
`expiration, with the use of thin-section images.
`Brain MRI was performed with the use of an
`8-channel phased-array head coil.
`Tumor volume is typically estimated with the
`use of orthogonal measurements, which assume
`that the masses are ellipsoid.15 However, angio-
`myolipomas often have complex shapes, resulting
`from asymmetrical growth or the coalescence of
`multiple lesions.2 MRI and CT are easily adapted
`for volumetric analysis.16,17 Because volumetric
`techniques are superior to diameter-based ap-
`proaches for measuring the size of tumors with
`complex shapes,18 we used a standardized vali-
`dated software program,19 similar to software
`used for other renal-volume determinations,20 for
`volumetric analyses of angiomyolipomas and cys-
`tic lung lesions. One investigator measured angio-
`myolipoma volumes. For validation, another inves-
`tigator independently measured the lesion volumes
`by measuring the three orthogonal diameters.
`
`Pulmonary Function and 6-Minute Walk
`Testing
`Testing was performed according to guidelines
`of the American Thoracic Society.21,22 Patients
`with lymphangioleiomyomatosis underwent com-
`plete pulmonary-function testing — including
`the measurement of spirometric variables, lung
`volumes, diffusing capacity, and the 6-minute
`walk distance — at baseline, 6 or 9 months, 12
`months, and 24 months; simple spirometric
`measurements were obtained at other study visits.
`Assessment of reversible airflow obstruction was
`
`Laboratory Studies
`To assess safety, at each visit we measured the
`levels of electrolytes, blood urea nitrogen, creati-
`nine, glucose, hepatic enzymes, bilirubin, serum
`lipids, and sirolimus, and performed a complete
`blood count and urinalysis.
`
`Statistical Analysis
`We estimated that 25 patients would be needed
`for our study to have a statistical power of 95%
`to detect the difference between a 0% reduction
`in the mean angiomyolipoma volume from the
`baseline value (the null hypothesis) and a 30% re-
`duction (the alternative hypothesis). A one-sided
`test was used, since angiomyolipomas do not
`spontaneously regress. An independent interim
`analysis was undertaken by the Cincinnati Chil-
`dren’s Hospital Biostatistical Core, after 10 pa-
`tients had completed 1 year of sirolimus therapy,
`to determine whether there was evidence of a re-
`duction in lesion volume and of adequate safety.
`Analyses were performed with the use of the
`Proc Mixed procedure with the Kenward–Roger
`correction (SAS software, version 9.1). To avoid
`bias due to missing data, least-square means
`(±SD) are reported. These are model-based es-
`timates calculated from parameter estimates.
`Separate analyses were performed for the angio-
`myolipoma volumes alone, those expressed as
`percentages of the baseline value, and the percent-
`ages of the predicted values for the pulmonary-
`function outcomes, which are comparisons of the
`patients’ pulmonary-function values with norma-
`tive values derived from population studies.
`For variables for which there was a significant
`difference between the means at baseline and
`follow-up, we also compared the least-square
`means at these time points. To estimate the
`slopes and determine whether the least-square
`means had changed significantly by 12 months,
`a random-coefficient model involving a spline
`function was applied. All tests reflected in Ta-
`bles 1 and 2 were conducted a priori. P values
`of less than 0.05 were considered to indicate
`statistical significance. Reported P values were
`not adjusted for multiple testing.
`
`142
`
`n engl j med 358;2 www.nejm.org
`
`january 10, 2008
`
`The New England Journal of Medicine
`
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
`
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0003
`
`

`
`Sirolimus for Angiomyolipoma in Tuberous Sclerosis or Lymphangioleiomyomatosis
`
`28 Patients with TSC or sporadic
`LAM were screened
`
`3 Were not enrolled
`2 Were ineligible
`1 Declined to participate
`
`25 Were enrolled
`7 Had TSC only
`12 Had TSC and LAM
`6 Had sporadic LAM
`
`16 Had pulmonary-outcome data
`11 With TSC and LAM
`5 With sporadic LAM
`
`5 Withdrew
`2 Withdrew consent
`2 Had an adverse event
`1 Was noncompliant
`
`Sirolimus
`therapy
`
`20 Had angiomyolipoma evalu-
`ation at 12 mo
`6 With TSC only
`8 With TSC and LAM
`6 With sporadic LAM
`
`11 Had pulmonary-outcome data
`6 With TSC and LAM
`5 With sporadic LAM
`
`2 Withdrew to use sirolimus
`off-label
`
`No sirolimus
`therapy
`
`18 Had angiomyolipoma evalu-
`ation at 24 mo
`6 With TSC only
`7 With TSC and LAM
`5 With sporadic LAM
`
`10 Had pulmonary-outcome data
`5 With TSC and LAM
`5 With sporadic LAM
`
`Figure 1. Overview of Screening, Enrollment, and Follow-up of the Patients with the Tuberous Sclerosis Complex
`(TSC) or Sporadic Lymphangioleiomyomatosis (LAM).
`Angiomyolipoma volumes and pulmonary-function tests in patients with LAM were assessed during the period of
`sirolimus treatment, from baseline to 12 months, and during a post-treatment observation period, from 12 to 24
`AUTHOR:
`Bissler
`1st
`RETAKE
`ICM
`months. At baseline, 18 patients had LAM, but pulmonary data were uninterpretable in 2 patients because of chylo-
`2nd
`FIGURE:
`1 of 4
`REG F
`thorax or pneumothorax. At the 12-month time point, one patient declined to undergo pulmonary-function tests,
`3rd
`CASE
`Revised
`and four patients had withdrawn from the study. One patient withdrew during the second year.
`4-C
`Line
`SIZE
`EMail
`ARTIST:
`ts
`H/T
`H/T
`33p9
`Combo
`
`Enon
`
`R esults
`
`Characteristics of the Patients
`JOB:
`35802
`The 25 study patients consisted of 5 men and
`2 women with the tuberous sclerosis complex only
`and 18 women with lymphangioleiomyomatosis,
`12 of whom had the tuberous sclerosis complex
`with lymphangioleiomyomatosis and 6 of whom
`had sporadic lymphangioleiomyomatosis only. Five
`patients with the tuberous sclerosis complex (four
`who also had lymphangioleiomyomatosis) left the
`study during the first year: two withdrew consent,
`one had pyelonephritis and recurrent diarrhea,
`
`AUTHOR,PLEASENOTE:
`one had a unilateral renal hemorrhage, and one
`Figurehasbeenredrawnandtypehasbeenreset.
`Pleasecheckcarefully.
`did not comply with the protocol (Fig. 1).
`In one patient with sporadic lymphangioleio-
`ISSUE:
`01-10-07
`myomatosis, the target serum sirolimus range of
`1 to 5 ng per milliliter was maintained, but in all
`other patients the dose was increased to the high-
`est range (10 to 15 ng per milliliter) on the basis
`of imaging results at 2 months and 4 months.
`Twenty patients underwent the 12-month eval-
`uation. Two patients withdrew from the study
`after the 12-month visit to continue sirolimus
`therapy off-label because of self-perceived bene-
`fit, leaving 18 patients at the 24-month assess-
`
`n engl j med 358;2 www.nejm.org
`
`january 10, 2008
`
`143
`
`The New England Journal of Medicine
`
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
`
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0004
`
`

`
`T h e ne w e ngl a nd jou r na l o f m e dicine
`
`Table 1. Response of Angiomyolipoma Volume to Sirolimus Therapy.*
`
`Value
`Least-square mean (95% CI)
`— ml
`Range — ml
`
`Least-square mean (95% CI)
`— % of baseline value
`P value for change from base-
`line value
`
`Baseline (N = 20)
`71.6±105.3 (24.9 to 118.2)
`
`12 Mo (N = 20)
`36.5±105.3 (−10.2 to 83.2)
`
`24 Mo (N = 18)
`18 Mo (N = 19)
`64.8±106.1 (18.1 to 111.6) 74.9±108.0 (27.8 to 121.9)
`
`1.0 to 389.0
`
`0.7 to 169.9
`
`0.7 to 357.2
`
`1.1 to 462.4
`
`53.2±26.6 (46.3 to 60.2)
`
`76.8±27.5 (69.7 to 83.9)
`
`85.9±28.5 (78.7 to 93.2)
`
`P<0.001
`
`P<0.001
`
`P = 0.005
`
`* Plus–minus values are least-square means ±SD. The least-square means were calculated with the use of the Proc Mixed procedure (SAS
` software, version 9.1). Some patients had withdrawn from the study by the 18-month and 24-month follow-up visits. The two hepatic
` angiomyolipomas studied had the same pattern of response as that shown here for the renal angiomyolipomas.
`
`ment of angiomyolipoma. Fourteen patients with
`lymphangioleiomyomatosis remained in the study
`for the second year, but chylothorax or pneumo-
`thorax at baseline precluded pulmonary-outcome
`assessments in two patients, and one patient who
`had the tuberous sclerosis complex with lymph-
`angioleiomyomatosis declined the 12-month pul-
`monary-function tests.
`Pulmonary end points after 1 year of receiv-
`ing sirolimus were available for 11 patients with
`lymphangioleiomyomatosis (6 with the tuberous
`sclerosis complex with lymphangioleiomyomato-
`sis and 5 with sporadic lymphangioleiomyoma-
`tosis). During the second year, 1 patient with
`lymphangioleiomyomatosis withdrew from the
`study to take the drug off-label; therefore, data
`for 10 patients with lymphangioleiomyomatosis
`were available for the 24-month analysis.
`
`Angiomyolipoma Burden
`The targeted renal angiomyolipoma lesions were
`bilateral in 12 of the 20 patients (60%) and unilat-
`eral in 6 of the 20 patients (30%). Hepatic angio-
`myolipoma lesions were targeted in the remaining
`two patients (10%). The mean (±SD) angiomyoli-
`poma volume at baseline was 71.6±105.3 ml (Ta-
`ble 1). After 12 months of therapy, the mean vol-
`ume decreased to 53.2±26.6% of the baseline
`volume (P<0.001). At 12 months, 16 of the 20 pa-
`tients for whom we had data for the first-year
`follow-up period (80%) had at least a 30% reduc-
`tion in angiomyolipoma volume (Fig. 2). At 6 and
`12 months after stopping sirolimus, the mean an-
`giomyolipoma volume had increased to 76.8±27.5%
`of the baseline volume (P<0.001) and 85.9±28.5%
`of the baseline volume (P = 0.005), respectively
`(Table 1 and Fig. 2). Angiomyolipomas in 5 of the
`18 patients (28%) remained at least 30% smaller
`
`1 year after therapy than they were at baseline.
`There was no correlation between statin use or
`lesion size at baseline and the response to siroli-
`mus (see the Supplementary Appendix, available
`with the full text of this article at www.nejm.org).
`The response of a renal angiomyolipoma after 12
`months of sirolimus therapy, visualized on MRI,
`is shown in Figure 3.
`The angiomyolipoma volumes were divided
`into three categories: small (<6.5 ml), medium
`(6.5–85.0 ml), and large (>85.0 ml). The size as-
`sessments obtained with the use of volumetric
`techniques and those obtained by means of mea-
`suring the orthogonal diameters were correlated
`for each category. The intraclass correlation co-
`efficients for the two methods ranged from 0.76
`to 0.86 (mean, 0.81; P<0.001) across the visits.
`The statistical significance of the measurements
`obtained through either method was similar.
`
`Pulmonary Studies
`Pulmonary structural and functional data for 11
`female patients with lymphangioleiomyomatosis
`are listed in Table 2. One patient was a current
`smoker, three were former smokers, and seven
`had never been smokers. At enrollment, spiro-
`metric measurements were normal in four pa-
`tients, revealed moderate airflow obstruction
`(forced expiratory volume in 1 second [FEV1], 50
`to 70% of the predicted value) in three patients,
`and indicated severe airflow obstruction (FEV1
`<50% of the predicted value) in four patients. Dur-
`ing sirolimus therapy, the mean FEV1 increased
`from the baseline mean by 120±230 ml at 6 months
`(P = 0.009) and by 118±330 ml at 12 months
`(P = 0.06), with 5 of the 11 patients gaining 100 ml
`or more in volume during therapy (Fig. 4A and
`4C). After 1 year of sirolimus therapy, the FEV1 in
`
`144
`
`n engl j med 358;2 www.nejm.org
`
`january 10, 2008
`
`The New England Journal of Medicine
`
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
`
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0005
`
`

`
`Sirolimus for Angiomyolipoma in Tuberous Sclerosis or Lymphangioleiomyomatosis
`
`oxide, FEV1 forced expiratory volume in 1 second, and FVC forced vital capacity.
`patients; 1 patient had withdrawn during the second year. Changes from baseline were not significant unless otherwise indicated. DlCO denotes diffusing capacity of the lung for carbon mon-
`function tests were uninterpretable, and 1 patient who declined to undergo pulmonary-function tests at the 12-month visit. Data for the 24-month study visit were available for 10 of these 11
`patients with lymphangioleiomyomatosis who completed the 12-month study visit; excluded were 2 patients with chylothorax or pneumothorax at baseline, for whom data from pulmonary-
`
`‖ P = 0.04 for the change from the baseline value.
`¶ P = 0.004 for the change from the baseline value.
`§ P = 0.01 for the change from the baseline value.
`‡ P = 0.02 for the change from the baseline value.
`† P<0.001 for the change from the baseline value.
`
`* Plus–minus values are least-square means ±SD. The least-square means were calculated with the use of the Proc Mixed procedure (SAS software, version 9.1). Data are listed for 11 of the 14
`
`23.91±60.23 (−18.53 to 66.35)−19.42±111.42 (−97.93 to 59.08)
`
`6-Minute walk distance (95% CI) — m485.30±82.87 (426.91 to 543.69)509.21±100.31 (438.53 to 579.89)465.88±160.65 (352.69 to 579.07)
`
`−3.46±8.15 (−7.26 to 0.34)
`
`−2.84±5.56 (−5.50 to −0.18)
`
`18.17±12.49 (10.01 to 26.34)
`
`18.79±12.32 (10.66 to 26.93)
`
`21.63±12.32 (13.50 to 29.77)
`
`Cyst volume (95% CI) — % of lung
`
`2.77±15.49 (−8.00 to 13.55)
`
`0.09±11.66 (−8.12 to 8.30)
`
`55.95±23.95 (39.18 to 72.73)
`
`53.27±14.62 (42.97 to 63.57)
`
`53.18±14.12 (43.24 to 63.12)
`
`Percent of predicted value (95% CI)
`
`volume
`
`−0.74±4.02 (−2.06 to 3.53)
`
`−0.08±2.67 (−1.80 to 1.96)
`
`13.82±7.35 (8.67 to 18.97)
`
`13.16±4.48 (10.01 to 16.32)
`
`104.78±28.42 (84.76 to 124.79)−27.00±27.06 (−46.07 to −7.94)§−22.86±31.45 (−44.74 to −0.98)‖
`
`100.64±25.17 (82.90 to 118.37)
`
`Least-square mean (95% CI) —
`DlCO
`Percent of predicted value (95% CI)127.64±46.52 (94.86 to 160.41)
`
`13.08±4.34 (10.02 to 16.14)
`
`ml/mm Hg/min
`
`−0.33±0.57 (−0.73 to 0.07)
`
`−0.44±0.49 (−0.79 to −0.09)‡
`
`1.97±0.55 (1.58 to 2.36)
`
`1.87±0.48 (1.53 to 2.20)
`
`2.30±0.84 (1.72 to 2.89)
`
`Least-square mean (95% CI) — liters
`
`−0.61±11.31 (−5.87 to 4.65)
`
`−0.64±7.68 (−4.34 to 3.06)
`
`98.48±15.65 (88.37 to 108.59)
`
`98.45±15.33 (88.39 to 108.52)
`
`Percent of predicted value (95% CI)99.09±15.33 (89.02 to 109.15)
`
`−0.02±0.59 (−0.30 to 0.26)
`
`−0.04±0.40 (−0.23 to 0.16)
`
`5.23±0.87 (4.66 to 5.81)
`
`5.22±0.86 (4.64 to 5.79)
`
`5.25±0.86 (4.68 to 5.82)
`
`Least-square mean (95% CI) — liters
`
`Total lung capacity
`
`9.83±17.81 (3.32 to 16.35)¶
`
`88.65±19.99 (75.60 to 101.70)10.36±14.19 (5.07 to 15.65)†
`
`89.18±19.72 (76.17 to 102.19)
`
`Percent of predicted value (95% CI)78.82±19.72 (65.81 to 91.83)
`
`0.35±0.71 (0.08 to 0.61)§
`
`0.39±0.57 (0.18 to 0.60)†
`
`3.34±0.86 (2.77 to 3.90)
`
`3.38±0.85 (2.81 to 3.95)
`
`2.99±0.85 (2.42 to 3.56)
`
`Least-square mean (95% CI) — liters
`
`Residual volume
`
`2.64±13.84 (−2.52 to 7.80)
`
`4.27±11.07 (0.11 to 8.44)
`
`60.37±22.73 (44.93 to 75.81)
`
`62.00±22.57 (46.58 to 77.42)
`
`57.2±22.57 (42.31 to 73.15)
`
`Percent of predicted value (95% CI)
`
`0.06±0.41 (−0.09 to 0.22)
`
`0.12±0.33 (−0.01 to 0.24)
`
`1.83±0.79 (1.29 to 2.38)
`
`1.89±0.79 (1.34 to 2.44)
`
`1.77±0.79 (1.23 to 2.32)
`
`Least-square mean (95% CI) — liters
`FEV1
`
`24 Mo (N = 10)
`
`12 Mo (N = 11)
`
`Change from Baseline
`
`24 Mo (N = 10)
`
`12 Mo (N = 11)
`
`Baseline (N = 11)
`
`Value
`
`Table 2. Pulmonary Structural and Functional Characteristics of Patients with Lymphangioleiomyomatosis.*
`
`FVC
`
`n engl j med 358;2 www.nejm.org
`
`january 10, 2008
`
`145
`
`The New England Journal of Medicine
`
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
`
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0006
`
`

`
`T h e ne w e ngl a nd jou r na l o f m e dicine
`
`ue (range, −190 to 1100 ml) (P<0.001) (Fig. 4B and
`4C). Eight of the 11 patients had an increase of at
`least 250 ml in FVC during the year of sirolimus
`therapy. The mean FVC remained 346±712 ml
`above the baseline mean at 24 months (P = 0.01),
`and the mean percent of the predicted FVC value
`was significantly improved at 12 months (P<0.001)
`and at 24 months (P = 0.004).
`The mean residual volume fell by 439±493 ml
`after 1 year of sirolimus therapy, as compared with
`the baseline value (P = 0.02). The six patients who
`had substantial air trapping at baseline (residual
`volume >120% of the predicted value) had a reduc-
`tion in the residual volume after 12 months of re-
`ceiving sirolimus (Fig. 4D). The improvement in
`the percent of the predicted residual volume re-
`mained significant at 24 months (P = 0.04), where-
`as the improvement for the absolute residual vol-
`ume did not (P = 0.09).
`The mean diffusing capacity of the lung for
`carbon monoxide (DlCO) was reduced in all but
`one patient at baseline (overall mean, 53.2±14.1%
`of the predicted value). Neither the DlCO nor the
`6-minute walk distance changed significantly dur-
`ing the study (Table 2).
`CT volumetric analysis of lung-cyst volume did
`not reveal a significant change (Table 2). For the
`year of sirolimus therapy, the correlation coeffi-
`cient between residual volume and FVC was −0.75
`(P = 0.01) and that between residual volume and
`cyst volume was 0.76 (P<0.001). There was no
`clear relationship between the reduction in angio-
`myolipoma volume and the pulmonary response
`to sirolimus in the study population. The chang-
`es in FEV1, FVC, and residual volume associated
`with sirolimus therapy were similar in the pa-
`tients who had the tuberous sclerosis complex
`with lymphangioleiomyomatosis and in those
`who had sporadic lymphangioleiomyomatosis,
`but there may have been too few patients in each
`subgroup to detect a significant difference.
`
`Neurologic Assessment
`All patients with the tuberous sclerosis complex
`had cortical tubers; 64% had subependymal nod-
`ules. None had hydrocephalus or giant-cell astro-
`cytomas. There were no changes in the size of
`the tubers, in the characteristics of the tubers on
`MRI, or in cerebral vasculature or perfusion.
`
`Adverse Events
`The most common adverse events included aph-
`thous ulcers, diarrhea, and upper respiratory in-
`
`120
`
`100
`
`80
`
`60
`
`40
`
`20
`
`(% of baseline value)
`
`Angiomyolipoma Volume
`
`Sirolimus therapy
`
`No sirolimus therapy
`
`0
`
`0
`
`6
`
`12
`Months
`
`18
`
`24
`
`Figure 2. Angiomyolipoma Volume in the Patients with the Tuberous
` Sclerosis Complex or Sporadic Lymphangioleiomyomatosis during the Study.
`AUTHOR:
`Bissler
`1st
`RETAKE
`ICM
`2nd
`FIGURE:
`2 of 4
`Angiomyolipomas were visualized with the use of abdominal magnetic reso-
`REG F
`3rd
`nance imaging, and volumetric analysis was performed at baseline and at 2,
`CASE
`Revised
`4-C
`Line
`4, 6, 12, 18, and 24 months. The angiomyolipoma volume at each visit is ex-
`SIZE
`EMail
`ARTIST:
`ts
`H/T
`H/T
`pressed as a percentage of the baseline size. The dashed line represents 70%
`4 col
`Enon
`Combo
`of the baseline value; data below the line indicate that the mean angiomyo-
`AUTHOR, PLEASE NOTE:
`lipoma volume was reduced by 30% or more.
`Figure has been redrawn and type has been reset.
`Please check carefully.
`
`JOB:
`
`35802
`
`ISSUE:
`
`01-10-07
`
`Baseline
`
`12Months
`
`Figure 3. Renal Angiomyolipomas in the Abdomen of a Patient with the Tu-
`berous Sclerosis Complex.
`Bissler
`AUTHOR:
`1st
`RETAKE
`ICM
`2nd
`Bilateral angiomyolipomas are shown at baseline and after 12 months of si-
` 3 of 4
`FIGURE:
`REG F
`3rd
`rolimus therapy. Three lesions in the left kidney are identified by arrows; at
`CASE
`Revised
`12 months, the top lesion had become reduced in size and the bottom two
`Line
`4-C
`SIZE
`EMail
`ARTIST:
`ts
`had become imperceptible. The images were obtained with the use of fast
`H/T
`H/T
`36p6
`Enon
`Combo
`spin–echo T2-weighted magnetic resonance imaging with fat suppression.
`AUTHOR,PLEASENOTE:
`Figurehasbeenredrawnandtypehasbeenreset.
`Pleasecheckcarefully.
`these patients was significantly improved (P = 0.002)
`35602
`01-10-07
`ISSUE:
`as compared with the expected decline in FEV1 for
`patients with lymphangioleiomyomatosis of 75 ml
`per year.23 Twelve months after stopping siroli-
`mus, the mean FEV1 was 62±411 ml greater than
`the mean baseline value.
`The forced vital capacity (FVC) at 12 months
`was increased by 390±570 ml over the baseline val-
`
`JOB:
`
`146
`
`n engl j med 358;2 www.nejm.org
`
`january 10, 2008
`
`The New England Journal of Medicine
`
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
`
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0007
`
`

`
`Sirolimus for Angiomyolipoma in Tuberous Sclerosis or Lymphangioleiomyomatosis
`
`12
`
`0
`
`6
`Sirolimus
`therapy
`
`No sirolimus
`therapy
`
`24
`
`Months
`
`35
`
`30
`
`25
`
`20
`
`15
`
`10
`
`5 0
`
`−5
`
`−10
`
`−15
`
`250
`
`200
`
`150
`
`100
`
`50
`
`FVC (% change from baseline value)
`
`Residual Volume (% of predicted value)
`
`B
`
`D
`
`12
`
`0
`
`6
`Sirolimus
`therapy
`
`No sirolimus
`therapy
`
`24
`
`Months
`
`P<0.001
`
`P=0.01
`
`FVC
`
`P=0.002
`
`P=0.009
`
`FEV1
`
`35
`
`30
`
`25
`
`20
`
`15
`
`10
`
`5 0
`
`−5
`
`−10
`
`−15
`
`500
`
`450
`
`400
`
`350
`
`300
`
`250
`
`200
`
`150
`
`100
`
`50
`
`0
`
` (% change from baseline value)
`
`FEV1
`
`Mean Change (ml)
`
`A
`
`C
`
`−50
`
`0
`
`12
`
`6
`Sirolimus
`therapy
`
`No sirolimus
`therapy
`
`24
`
`Months
`
`0
`
`0
`
`12
`
`9
`6
`Sirolimus
`therapy
`
`No sirolimus
`therapy
`
`24
`
`Months
`
`Figure 4. Pulmonary Function in Patients with Lymphangioleiomyomatosis.
`Panel A shows the forced expiratory volume in 1 second (FEV1) for each patient. Panel B shows the forced vital capacity
`(FVC) for each patient. Panel C shows the mean change (in milliliters) from the baseline values for FEV1 and for FVC.
`I bars indicate the standard errors. Panel D shows the residual volume for each patient.
`
`ICM
`REG F
`
`Bissler
`AUTHOR:
`FIGURE:
`4 of 4
`
`RETAKE
`
`1st
`2nd
`3rd
`
`CASE
`
`EMail
`
`Revised
`Line
`4-C
`SIZE
`ARTIST:
`ts
`H/T
`H/T
`33p9
`Enon
`Combo
`january 10, 2008
`n engl j med 358;2 www.nejm.org
`AUTHOR, PLEASE NOTE:
`Figure has been redrawn and type has been reset.
`Please check carefully.
`
`JOB:
`
`35802
`
`ISSUE:
`
`01-10-07
`
`147
`
`The New England Journal of Medicine
`
`Downloaded from nejm.org on November 30, 2016. For personal use only. No other uses without permission.
`
` Copyright © 2008 Massachusetts Medical Society. All rights reserved.
`
`Ex. 1093-0008
`
`

`
`T h e ne w e ngl a nd jou r na l o f m e dicine
`
`Table 3. Adverse Events.*
`
`Category
`
`No. of
`Patients
`
`No. of
`Events
`
`Gastrointestinal
`Aphthous ulcer or mucositis
`Diarrhea
`Infection
`Upper respiratory infection, sinusitis,
`or bronchitis
`Pneumonia
`Pharyngitis
`Cellulitis
`Urinary tract infection or pyelonephritis
`Conjunctivitis
`Salivary gland infection
`Skin-related
`Folliculitis
`Acne
`Other
`Metabolic or laboratory
`Hyperlipidemia
`Hypokalemia
`Pain
`Headache
`Abdominal or flank pain
`Other
`Pulmonary or upper respiratory
`Dyspnea
`Hypoxia
`With exercise
`At rest
`Pneumothorax
`Cough
`Abnormality on radiography
`Allergic rhinitis
`Sexual or reproductive function
`Irregular menses
`Ovarian or breast cyst
`Musculoskeletal or soft-tissue swelling
`Cardiac
`Hypertension
`Palpitations or arrhythmia
`Hemorrhage
`Renal

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket